By comprehensively comparing the spatial transcriptomics profiles of more than 1800 genes related to cancer biology, TME and immune responses between a sizable cohort of patients treated with NAT versus those who were NAT-naïve, we demonstrated that NAT induced 44 DEGs in carcinoma cells and 52 DEGs in the TME. The gene discussed is BRD2; the disease is carcinoma.